A Phase I Trial of WP1066 in Patients With Recurrent Malignant Glioma and Brain Metastasis From Melanoma

Trial Profile

A Phase I Trial of WP1066 in Patients With Recurrent Malignant Glioma and Brain Metastasis From Melanoma

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs WP 1066 (Primary)
  • Indications Brain metastases; Glioblastoma; Glioma; Malignant melanoma
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 05 Dec 2017 According to a Moleculin Biotech media release, Investigational New Drug (IND) application for this trial has been approved by the US Food and Drug Administration (FDA).
    • 07 Nov 2017 Planned End Date changed from 1 Mar 2021 to 1 Mar 2022.
    • 01 Nov 2017 According to a Moleculin Biotech media release, the responses to the US FDA requests for additional information relating to the physician-sponsored Investigational New Drug (IND) application have been submitted.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top